Bart Vanhaesebroeck
Bart Vanhaesebroeck FRS[1] is a Belgian-UK scientist based at University College London. Vanhaesebroeck is Professor of Cell Signalling at the UCL Cancer Institute.
Career
Vanhesebroeck earned a licentiate in 1985 and a PhD in 1990, both from the University of Ghent. He then performed postdoctoral studies with Michael Waterfield at the Ludwig Institute for Cancer Research (London Branch) where he set up his independent research group in 1998. He became Professor at University College London in 2005 and Associate Member of the Ludwig Institute for Cancer Research in 2006. In 2007, he moved to Barts Cancer Institute at Queen Mary University of London to set up the Centre for Cell Signalling. In 2014, he became Professor of Cell Signalling at the UCL Cancer Institute.
Research interests
Vanhaesebroeck's research team has made fundamental discoveries in the field of cell signalling by lipid second messengers, work which has led to approved medicines for leukemia.
Vanhaesebroeck’s contributions include uncovering the functions of PI 3-kinase (PI3K) family members[2] and the identification of PI3Kd,[3] the main PI3K in white blood cells, in which it controls immune functions.[4] His work has underpinned the generation of PI3Kd inhibitors that are currently used in the treatment of haematological malignancies and are being trialled in cancer immunotherapy of solid tumours.[5] His team’s development of small molecule PI3K activators has opened new avenues for kinase drug development and their therapeutic applications.
Awards and honours
Vanhaesebroeck was elected as a Member of the European Molecular Biology Organisation (2012) and a Fellow of the Royal Society of Biology (2011), the Academy of Medical Sciences (2016) and the Royal Society (2024).
Additional information
[1] Cell Signalling Research Group
[2] 30 years of PI3K: an interview with Bart Vanhaesebroeck
See also
- Phosphoinositide 3-kinase
- P110δ
- Walter Fiers
- Michael Waterfield
References
- ↑ "Professor Bart Vanhaesebroeck FRS". Fellow Detail Page. Royal Society. Retrieved 2024-07-09.
- ↑ Vanhaesebroeck, Bart; Stephens, L; Hawkins, P (2012). "PI3K signalling: the path to discovery and understanding". Nat Rev Mol Cell Bio. 13 (3): 195–203. doi:10.1038/nrm3290. PMID 22358332.
- ↑ Vanhaesebroeck, Bart; Welham, Melanie J.; Kotani, Kei; Stein, Rob; Warne, Patricia H.; Zvelebil, Markéta J.; Higashi, Kyoichiro; Volinia, Stefano; Downward, Julian; Waterfield, Michael D. (1997-04-29). "p110δ, a novel phosphoinositide 3-kinase in leukocytes". Proceedings of the National Academy of Sciences. 94 (9): 4330–4335. Bibcode:1997PNAS...94.4330V. doi:10.1073/pnas.94.9.4330. ISSN 0027-8424. PMC 20722. PMID 9113989.
- ↑ Okkenhaug, Klaus; Bilancio, Antonio; Farjot, Géraldine; Priddle, Helen; Sancho, Sara; Peskett, Emma; Pearce, Wayne; Meek, Stephen E.; Salpekar, Ashreena; Waterfield, Michael D.; Smith, Andrew J. H.; Vanhaesebroeck, Bart (2002-08-09). "Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice". Science. 297 (5583): 1031–1034. doi:10.1126/science.1073560. ISSN 0036-8075. PMID 12130661.
- ↑ Ali, Khaled; Soond, Dalya R.; Piñeiro, Roberto; Hagemann, Thorsten; Pearce, Wayne; Lim, Ee Lyn; Bouabe, Hicham; Scudamore, Cheryl L.; Hancox, Timothy; Maecker, Heather; Friedman, Lori; Turner, Martin; Okkenhaug, Klaus; Vanhaesebroeck, Bart (2014-06-19). "Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer". Nature. 510 (7505): 407–411. Bibcode:2014Natur.510..407A. doi:10.1038/nature13444. ISSN 0028-0836. PMC 4501086. PMID 24919154.
This article "Bart Vanhaesebroeck" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Bart Vanhaesebroeck. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
